



David Paul Richman, M.D.

Clinical Interests	David P. Richman's professional interests include biochemistry and pharmacology of the nicotinic acetylcholine receptor and muscle-specific kinase (MuSK), diseases of neuromuscular transmission, myasthenia gravis, anti-MuSK myasthenia, and Lambert-Eaton myasthenic syndrome, and the pathogenesis and control of autoimmune response in myasthenia gravis. Richman has coauthored an extensive list of publications and book chapters on neurological disease and related topics.
Title	Professor
Specialty	Neurology - Neuroimmunology, Myasthenia Gravis
Department	Neurology
Division	Neurology UC Davis Medical Group, Sacramento - Midtown
Address/Phone	UC Davis Midtown Ambulatory Care Center, Midtown Neurology Clinic, 3160 Folsom Blvd Suite 2100 Sacramento, CA 95816 Phone: 916-734-3588
Additional Phone	Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Education	M.D., Johns Hopkins University School of Medicine, Baltimore MD 1969 A.B., Princeton University, Princeton NJ 1965
Internships	Albert Einstein College of Medicine, New York City NY 1969-1970
Residency	Neurology, Albert Einstein College of Medicine, New York City NY 1970-1971 Chief Resident, Neurology, Massachusetts General Hospital, Boston MA 1973-1974
Fellowships	Neurology, Harvard Medical School, Boston MA 1974-1975 Research Neurology, Massachusetts General Hospital, Boston MA 1974-1976
Board Certifications	American Board of Psychiatry and Neurology, 1976
Professional Memberships	American Academy of Neurology American Association of Immunologists American Neurological Association
Select Recent Publications	Renton AE, Pliner HA, Carlo Provenzano et al. A genome-wide association study of myasthenia gravis. JAMA Neurol. 2015;72:396-404.



David Paul Richman, M.D.

The Huntington Study Group PHAROS Investigators. Clinical-Genetic Specificity in the Prospective Huntington At-Risk Observational Study (PHAROS): implications for clinical trials. *JAMA Neurol.* 2016;73(1):102-10.

Oskarsson B, Rocke DM, Dengel K, Richman DP. Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study. *Neurology.* 2016 Feb 5.

Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM Jr, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM Jr, Hehir MK, Hobson-Webb LD, Howard JF Jr, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. *Muscle Nerve.* 2016 Feb;53(2):165-8.

Rostedt Punga A, Kaminski HJ, Richman DP, Benatar M. How clinical trials of myasthenia gravis can inform pre-clinical drug development. *Exp Neurol.* 2015 Aug;270:78-81.

Richman DP. The Future of Research in Myasthenia. *JAMA Neurol.* 2015 Jul;72(7):812-4.



David Paul Richman, M.D.

Ha JC, Richman DP. Myasthenia gravis and related disorders: Pathology and molecular pathogenesis. *Biochim Biophys Acta*. 2015 Apr;1852(4):651-7.

Morell SW, Trinh VB, Gudipati E, Friend A, Page NA, Agius MA, Richman DP, Fairclough RH. Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor. *Mol Immunol*. 2014 Mar;58(1):116-31.

Kim SS, Richman DP, Johnson WO, Hald JK, Agius MA. Limited utility of current MRI criteria for distinguishing multiple sclerosis from common mimickers: primary and secondary CNS vasculitis, lupus and Sjogren's syndrome. *Mult Scler*. 2014 Jan;20(1):57-63.

Richman DP. Neurologic emergency: acute neuromuscular weakness. *Audio-Digest Internal Medicine*. 61 (28). July 28, 2014. ISSN 0271-1303.

© 2017 UC Regents